Quantgene
Dr. Ilia Ichetovkin, Ph.D. is the Chief Scientific Officer at Quantgene. Before joining Quantgene, he spent 20 years at several biotech companies developing and commercializing highly complex diagnostic products in the areas of molecular oncology and metabolic diseases. His experience spans from CLIA laboratory operations to successful regulatory submissions of IVD and CDx products. He has worked as VP of Diagnostic Strategies at Rhythm Pharmaceuticals, Head of Oncology R&D at Vela Diagnostics, as Head of Clinical Diagnostics and Biomarker Development at Celgene/Abraxis,and as Director of U.S. Laboratory Operations with LabCorp Clinical Trials.
Dr. Ichetovkin has a Ph.D. in Biomedical Sciences from Albert Einstein College of Medicine and M.S. in chemistry from Moscow State University.
This person is not in any offices
Quantgene
Medical technology now allows for cancer to be detected in a patient’s blood through cell-free DNA (cfDNA). Quantgene has developed a method for Deep Human Genome sequencing which allows us to see mutational patterns of disease down to a single molecule. This means diseases like cancer can be detected far earlier than ever before.